Wolfgang Sadee

Summary

Publications

  1. ncbi request reprint Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities
    Wolfgang Sadee
    Department of Pharmacology, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    Life Sci 76:1427-37. 2005
  2. pmc Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk
    Audrey C Papp
    Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 7:e31930. 2012
  3. doi request reprint Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver
    Amy Webb
    Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Pharmacogenet Genomics 23:269-78. 2013
  4. pmc Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder
    Julia K Pinsonneault
    Department of Pharmacology, The Ohio State University, Columbus, OH 43210 1239, USA
    Neuropsychopharmacology 36:1644-55. 2011
  5. pmc Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse
    Robert A Moyer
    Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH 43210 1239, USA
    Neuropsychopharmacology 36:753-62. 2011
  6. pmc Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity
    Danxin Wang
    Department of Pharmacology, Program in Pharmacogenomics, School of Biomedical Science, Ohio State University, Columbus, Ohio 43210, USA
    Pharmacogenet Genomics 21:652-64. 2011
  7. pmc Whole transcriptome RNA-Seq allelic expression in human brain
    Ryan M Smith
    Department of Pharmacology, Program in Pharmacogenomics College of Medicine, The Ohio State University Wexner Medical Center, 5184A Graves Hall, 333 West 10th Avenue, Columbus, OH 43210, USA
    BMC Genomics 14:571. 2013
  8. pmc mRNA transcript diversity creates new opportunities for pharmacological intervention
    Elizabeth S Barrie
    Program in Pharmacogenomics, Department of Pharmacology, The Ohio State University, Columbus, OH 43210, USA
    Mol Pharmacol 81:620-30. 2012
  9. pmc Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms
    Ryan M Smith
    Neuroscience Graduate Studies Program, Department of Pharmacology, The Ohio State University, Columbus, OH 43210, USA
    Eur J Hum Genet 19:76-83. 2011
  10. pmc Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues
    Andrew D Johnson
    Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Pharmacogenet Genomics 18:781-91. 2008

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities
    Wolfgang Sadee
    Department of Pharmacology, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    Life Sci 76:1427-37. 2005
    ..Neutral antagonists are promising drug candidates in the treatment of addiction and overdose, and of peripheral adverse effects of narcotic analgesics...
  2. pmc Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk
    Audrey C Papp
    Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 7:e31930. 2012
    ..Similar to earlier results linking low CETP activity with poor outcomes in males, our results suggest genetic, sex-dependent CETP splicing effects on cardiovascular risk by a mechanism independent of circulating HDL-C levels...
  3. doi request reprint Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver
    Amy Webb
    Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Pharmacogenet Genomics 23:269-78. 2013
    ..Membrane transporters control the influx and efflux of endogenous and xenobiotic substrates, including nutrients and drugs, across cellular membranes...
  4. pmc Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder
    Julia K Pinsonneault
    Department of Pharmacology, The Ohio State University, Columbus, OH 43210 1239, USA
    Neuropsychopharmacology 36:1644-55. 2011
    ..1, p = 0.03). This result was replicated in a second bipolar/control population (OR = 1.65, p = 0.01), supporting a critical role for DAT regulation in bipolar disorder...
  5. pmc Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse
    Robert A Moyer
    Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH 43210 1239, USA
    Neuropsychopharmacology 36:753-62. 2011
    ..Our results confirm the role of rs2283265/rs1076560 in D2 alternative splicing and support a strong role in susceptibility to cocaine abuse...
  6. pmc Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity
    Danxin Wang
    Department of Pharmacology, Program in Pharmacogenomics, School of Biomedical Science, Ohio State University, Columbus, Ohio 43210, USA
    Pharmacogenet Genomics 21:652-64. 2011
    ..This study characterizes regulatory polymorphisms and underlying mechanisms of NAT1 expression...
  7. pmc Whole transcriptome RNA-Seq allelic expression in human brain
    Ryan M Smith
    Department of Pharmacology, Program in Pharmacogenomics College of Medicine, The Ohio State University Wexner Medical Center, 5184A Graves Hall, 333 West 10th Avenue, Columbus, OH 43210, USA
    BMC Genomics 14:571. 2013
    ..Accounting for these factors, we subsequently surveyed the variability of RNA editing across brain regions and across individuals...
  8. pmc mRNA transcript diversity creates new opportunities for pharmacological intervention
    Elizabeth S Barrie
    Program in Pharmacogenomics, Department of Pharmacology, The Ohio State University, Columbus, OH 43210, USA
    Mol Pharmacol 81:620-30. 2012
    ..Consideration of a gene's transcript diversity should become an integral part of drug design, development, and therapy...
  9. pmc Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms
    Ryan M Smith
    Neuroscience Graduate Studies Program, Department of Pharmacology, The Ohio State University, Columbus, OH 43210, USA
    Eur J Hum Genet 19:76-83. 2011
    ..Ethnic differences in LD across the CHRNA5 locus require consideration of upstream enhancer variants when testing clinical associations...
  10. pmc Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues
    Andrew D Johnson
    Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Pharmacogenet Genomics 18:781-91. 2008
    ..We have used AEI to discover and characterize regulatory polymorphisms in OPRM1, TPH2, MDR1, DRD2, and VKORC1. The objective of this study was to use AEI to determine the extent of cis-regulatory factors in pharmacogenetic genes...
  11. pmc Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex
    Ryan M Smith
    Department of Pharmacology, Program in Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, OH, USA
    Biol Psychiatry 73:546-54. 2013
    ..Despite hundreds of genetic associations investigating HTR2A polymorphisms in neuropsychiatric disorders and therapies, the role of genetic HTR2A variability in health and disease remains uncertain...
  12. pmc A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 15:5895-901. 2009
    ..HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC...
  13. pmc CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control
    JOSEPH PAUL KITZMILLER
    Department of Pharmacology, The Ohio State University, Columbus, OH, USA
    Drug Metabol Drug Interact 28:59-63. 2013
    ..CYP3A4/5 combined genotype approaches have proved useful in some studies involving CYP3A substrates. We intend to compare a combined genotype analysis to our previously reported single gene CYP3A4 analysis...
  14. pmc Innate immune gene polymorphisms in tuberculosis
    Abul K Azad
    Department of Microbial Infection and Immunity, Center for Microbial Interface Biology, The Ohio State University, Columbus, Ohio, USA
    Infect Immun 80:3343-59. 2012
    ....
  15. pmc Institutional profile: program in pharmacogenomics at the ohio state university medical center
    Joseph P Kitzmiller
    The Ohio State University Medical Center, Columbus, OH 43210, USA
    Pharmacogenomics 13:751-6. 2012
    Established in 2002, the Ohio State University Medical Center Program in Pharmacogenomics, lead by Wolfgang Sadee, is comprised of nearly 50 members dedicated to the discovery, investigation and translation of genetic biomarkers with the ..
  16. doi request reprint Genomics and personalized medicine
    Wolfgang Sadee
    Program in Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, OH 43210 1239, USA
    Int J Pharm 415:2-4. 2011
    ..e., they can be used to guide therapy. I will focus on pharmacogenetic biomarkers, highlighting current successes but also the main challenges that remain in optimizing individualized therapy...
  17. ncbi request reprint Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment
    Danxin Wang
    Department of Pharmacology, School of Medicine and Public Health, The Ohio State University, 333 West 10th Ave, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 321:544-52. 2007
    ..Activity profiles at the three opioid receptors under different conditions could lead to antagonists with optimal clinical properties in treatment of addiction and adverse opioid effects...
  18. pmc Allelic mRNA expression of sortilin-1 (SORL1) mRNA in Alzheimer's autopsy brain tissues
    Houda Alachkar
    Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH 43210 1239, United States
    Neurosci Lett 448:120-4. 2008
    ..Since each of these SNPs was heterozygous in several subjects lacking AEI, this study fails to support a regulatory role for SORL1 polymorphisms in mRNA expression...
  19. pmc Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others
    Joseph P Kitzmiller
    Department of Pharmacology, Division of Clinical Trials, College of Medicine, The Ohio State University, Columbus, USA
    Cleve Clin J Med 78:243-57. 2011
    ..It also discusses the future role of pharmacogenomic testing in medicine...
  20. pmc Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition
    Wenjun Ni
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 5:e13792. 2010
    ..This study aimed to evaluate pharmacogenetic factors associated with inter-individual variability in pharmacokinetics and outcomes associated with flavopiridol therapy...
  21. pmc Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene
    Brian E Roe
    Department of Agricultural, Environmental and Development Economics, Ohio State University, Columbus, Ohio, USA
    PLoS ONE 4:e6704. 2009
    ....
  22. pmc Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents
    Wenrui Duan
    Comprehensive Cancer Center, Division of Medical Oncology, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, USA
    Transl Res 161:156-64. 2013
    ..The use of paraffin-embedded tissues renders the reported method suitable for large-scale screening to select patients for treatment with DNA interstrand crosslinking agents, poly ADP-ribose polymerase inhibitors, or their combination...
  23. pmc Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect
    Wolfgang Sadee
    Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Pharmacogenomics 12:675-80. 2011
    ..g., 5-HTTLPR). This article focuses on molecular and functional diversity of genetic biomarkers, as a guide to optimal use in personalized medicine...
  24. pmc Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
    Danxin Wang
    Department of Pharmacology, Program in Pharmacogenetics, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Blood 112:1013-21. 2008
    ..Increased warfarin dose requirement in blacks was accounted for by lower frequency of the -1639 A allele. Therefore, -1639G>A is a suitable biomarker for warfarin dosing across ethnic populations...
  25. pmc Synaptic signaling and aberrant RNA splicing in autism spectrum disorders
    Ryan M Smith
    Program in Pharmacogenomics, Department of Pharmacology, The Ohio State University Columbus, OH, USA
    Front Synaptic Neurosci 3:1. 2011
    ..Here, we review the relationship between aberrant RNA splicing of synapse-related genes and autism spectrum disorders...
  26. pmc Allele-specific tumor spectrum in pten knockin mice
    Hui Wang
    Department of Molecular Genetics, College of Biological Sciences, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:5142-7. 2010
    ..These data demonstrate that the variable tumor phenotypes observed in patients with Cowden and BRR syndromes can be attributed to specific mutations in PTEN that alter protein function through distinct mechanisms...